UNIVERSITY OF COPENHAGEN

Inflammatory biomarkers and cancer

CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer

Rasmussen, Line Jee Hartmann; Schultz, Martin; Gaardsting, Anne; Ladelund, Steen; Garred, Peter; Iversen, Kasper; Eugen-Olsen, Jesper; Helms, Morten; David, Kim Peter; Kjaer, Andreas; Lebech, Anne-Mette; Kronborg, Gitte

Published in:
International Journal of Cancer

DOI:
10.1002/ijc.30732

Publication date:
2017

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY-NC

Citation for published version (APA):
Rasmussen, L. J. H., Schultz, M., Gaardsting, A., Ladelund, S., Garred, P., Iversen, K., ... Kronborg, G. (2017). Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer. *International Journal of Cancer*, *141*, 191-199. https://doi.org/10.1002/ijc.30732

Download date: 08. apr.. 2020

Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer

Line Jee Hartmann Rasmussen [1], Martin Schultz[2], Anne Gaardsting[3], Steen Ladelund[1], Peter Garred[4], Kasper Iversen[2], Jesper Eugen-Olsen[1], Morten Helms[3], Kim Peter David[3], Andreas Kjær[5], Anne-Mette Lebech[3] and Gitte Kronborg[3]

[1] Clinical Research Centre, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark
[2] Department of Cardiology, Copenhagen University Hospital Herlev, Herlev, Denmark
[3] Department of Infectious Diseases, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark
[4] Laboratory of Molecular Medicine, Department of Clinical Immunology, Rigshospitalet, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
[5] Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet, Denmark

In Denmark, patients with serious nonspecific symptoms and signs of cancer (NSSC) are referred to the diagnostic outpatient clinics (DOCs) where an accelerated cancer diagnostic program is initiated. Various immunological and inflammatory biomarkers have been associated with cancer, including soluble urokinase plasminogen activator receptor (suPAR) and the pattern recognition receptors (PRRs) pentraxin-3, mannose-binding lectin, ficolin-1, ficolin-2 and ficolin-3. We aimed to evaluate these biomarkers and compare their diagnostic ability to classical biomarkers for diagnosing cancer in patients with NSSC. Patients were included from the DOC, Department of Infectious Diseases, Copenhagen University Hospital Hvidovre. Patients were given a final diagnosis based on the combined results from scans, blood work and physical examination. Weight loss, Charlson score and previous cancer were registered on admission, and plasma concentrations of biomarkers were measured. The primary outcome was incident cancer within 1 year. Out of 197 patients included, 39 patients (19.8%) were diagnosed with cancer. Patients with cancer were significantly older and had a higher burden of comorbidities and previous cancer diagnoses compared to patients who were not diagnosed with cancer. Previous cancer, C-reactive protein (CRP) and suPAR were significantly associated with newly diagnosed cancer during follow-up in multiple logistic regression analyses adjusted for age, sex and CRP. Neither any of the PRRs investigated nor self-reported weight loss was associated with cancer. In this study, previous cancer, CRP and suPAR were significantly associated with cancer diagnosis in patients with NSSC. Ficolin-1-3, MBL and pentraxin-3 were not associated with cancer.

Cancer is the leading cause of death in Denmark. To reduce diagnostic delay and improve survival, between 2007 and 2012, the Danish Health Authority introduced standardized fast-track outpatient cancer pathways. A pathway was designed for patients with serious nonspecific symptoms and signs of disease that could be cancer (NSSC) and patients with metastasis without a known primary tumor or organ-specific manifestation. These patients undergo an accelerated pathway of cancer diagnostics at

Tumor Markers and Signatures

What's new?

In Denmark, patients with serious non-specific symptoms and signs of cancer are referred to an accelerated cancer diagnostic program. But screening and diagnosis is challenging as patients form a heterogeneous group. Possible advances in the diagnostic strategy must be studied to improve accuracy and safety. This study found that the novel inflammatory biomarker suPAR and the routinely evaluated inflammatory biomarker CRP were independently associated with incident cancer diagnoses, while the innate immune markers, pentraxin-3, mannose-binding lectin and ficolin-1-3, were not. Addition of suPAR to the existing blood samples may improve diagnosis and prognostication of cancer in this heterogeneous patient group.

the diagnostic outpatient clinics (DOCs). The prevalence of cancer diagnosed at Danish DOCs is 16–20%.[1–3] The remaining patients are found to have a wide range of nonmalignant diseases, but 25–50% of the patients leave the DOCs without a specific diagnosis.[1,2]

Screening and diagnosis is challenging as patients referred to the DOCs form a heterogeneous group. Possible advances in the diagnostic strategy must be studied to improve accuracy and safety when examining patients suspected of having serious disease.

Patients are characterized by different nonspecific complaints, such as weight loss, fatigue, diffuse abdominal or bone pain, anemia or an increase in drug usage or more frequent contacts with the health care system.[1] The initial diagnostic process at the DOC includes a focused medical history, a physical examination, application of an expanded panel of biochemical analyses and, if malignancy remains suspected, imaging is performed.[3]

Research has recently reported various immunological and inflammatory serum biomarkers associated with different types of cancer that could constitute new diagnostic or prognostic markers in the development of cancer and prognosis.[4–6]

Fluid-phase pattern recognition receptors (PRRs) of the innate immune system, including pentraxin-3, mannose-binding lectin (MBL), ficolin-1, ficolin-2 and ficolin-3, recognize pathogens and modified self-molecules and have been found to be associated with cancer.[7–17] Another novel biomarker in this setting is the soluble urokinase plasminogen activator receptor (suPAR) which reflects inflammatory activity. suPAR is the soluble form of uPAR which, in cancer, is expressed on cancer cells and stromal cells.[18–20] Several studies show an association between suPAR and the presence and prognosis of different types of cancer[21–27] as well as an increased risk of developing lung cancer in the general population.[28]

Little is known as to how these biomarkers perform in a heterogeneous group of patients with diffuse and nonspecific symptoms. Therefore, we evaluated these novel biomarkers and compared their diagnostic ability to that of classical biomarkers for diagnosing cancer in patients with NSSC.

Materials and Methods
Study design and patient inclusion
The current study of biomarkers in the DOC was conducted as part of a study evaluating two different diagnostic imaging modalities, ^{18}F-FDG-PET/CT vs. conventional CT of the thorax and abdomen.[3]

Patients were prospectively included from the DOC, Department of Infectious Diseases, Copenhagen University Hospital Hvidovre between August 14, 2013, and April 30, 2014. Patients were referred from their general practitioner, a medical specialist or other hospital departments. The criteria for referral to the DOC were suspicion of serious illness or suspicion of metastasis without a known primary tumor, based on one or more of the following symptoms present that do not fit into any of the organ-specific cancer diagnostic programs: general malaise, severe tiredness, unintentional weight loss, fever of unknown cause, uncharacteristic abdominal pain for >4 weeks, anemia, abnormal laboratory tests (e.g., elevated alkaline phosphatase levels, erythrocyte sedimentation rate (ESR), calcium etc.), diffuse bone pain, pathologically enlarged lymph nodes, marked increase in drug usage or increasing health service seeking behavior.

Inclusion criteria for the study were i) age ≥18 years, ii) referred to the DOC due to nonspecific symptoms or signs of cancer and iii) signed informed consent. Exclusion criteria were i) pregnancy, including risk of pregnancy and lactation, ii) alcohol or drug abuse hampering the ability to adhere to the protocol, iii) claustrophobia, iv) bodyweight above 150 kg, v) contraindications to CT due to allergy to contrast or impaired renal function defined as P-creatinine level >0.120 mmol/L or vi) deemed unfit due to performance status.

Randomization and clinical evaluation was performed as previously described.[3] Briefly, at the first visit to the DOC, patients were randomized 1:1 to be scanned with either conventional CT or ^{18}F-FDG-PET/CT. The randomization was based on a computer-generated list (GraphPad Software, Inc., La Jolla, CA) and was performed by a study nurse blinded to the patient's medical history, prior to any laboratory testing. Experienced certified radiologists and nuclear medicine physicians analyzed the CT or ^{18}F-FDG-PET/CT data and discussed the results with the clinicians. Furthermore, patients went through a physical examination including evaluation of biochemistry. The combined results from scans, blood work and physical examination provided the basis for the diagnostic decisions made by the DOC physicians at a multidisciplinary conference with the participation of specialist physicians from the following medical specialties: endocrinology, gastroenterology, nuclear medicine, radiology and infectious diseases. A preliminary tentative

Tumor Markers and Signatures

diagnosis was given here, and a final referral diagnosis was given when the full investigational program for disease at the DOC was complete. If a malignant diagnosis was established, the patients were referred to further treatment.

Patients were followed for 12 months after finishing their investigations in the DOC by reviewing the electronic medical records, for confirmation of malignant diagnoses based on pathology results from biopsies etc.

Measurements
Weight loss and previous cancer diagnoses were self-reported measures, registered in the electronic medical records at the first visit to the DOC.

Albumin, CRP, hemoglobin, lactate dehydrogenase, ESR and white blood cell count were analyzed as part of the routine evaluation at the Department of Clinical Biochemistry, Copenhagen University Hospital Hvidovre.

Plasma suPAR levels were analyzed with the suPARnostic AUTO Flex ELISA (ViroGates A/S, Birkerød, Denmark) on an automated Siemens BEP2000 platform at the Department of Clinical Biochemistry according to the manufacturer's instructions.

Plasma concentrations of ficolin-1, ficolin-2, ficolin-3, pentraxin-3 and MBL were determined by sandwich ELISAs using specific in house-produced monoclonal antibodies as previously described.[29–33] All assays were optimized for automated analysis in 384-well format on Biomek FX (Beckman Coulter, Fullerton, CA).

The Charlson comorbidity index (Charlson score) was assessed at the first consultation at the DOC by reviewing the patient's medical record.

Outcomes and covariates
The primary outcome was any incident cancer diagnoses within 1 year.

Multivariate analyses were adjusted for age and sex, and furthermore, as CRP is a widely used marker of inflammation in the clinic, we included CRP in the adjusted analyses.

Statistical analysis
Continuous variables are presented as mean and standard deviation (SD) or median and interquartile range (IQR). Categorical variables are presented as number and percentage.

Differences between groups were tested with *t*-test, Fisher's exact test or the Wilcoxon two-sample test where appropriate.

Associations were analyzed by multiple logistic regression. For these analyses, weight loss was categorized in groups per 5 kg weight loss, hemoglobin was log(1.1)-transformed and albumin, lactate dehydrogenase, CRP, ESR, suPAR, ficolin-1, ficolin-2, ficolin-3, MBL and pentraxin-3 were log(2)-transformed.

Kendall's Tau-b correlation coefficient was reported for pairwise correlation analyses for CRP, ESR and suPAR.

Biomarker discriminative abilities with regards to cancer were evaluated with area under the curve (AUC) for receiver operating characteristic (ROC) curves and logistic regression


Figure 1. Flow-chart for the study population.

analyses, calculating sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV) for adjusted models. The Youden's index was used as cutoff value.[34]

SAS Enterprise Guide 7.11 (SAS Institute, Cary, NC) and R 3.2.2 (The R Foundation, Vienna Austria) were used for statistical analysis. Figures were created with GraphPad Prism 6.07 (GraphPad Software, Inc., La Jolla, CA).

A *p*-value <0.05 was considered to be statistically significant.

Ethical considerations
All patients received oral and written information and gave written consent before inclusion. The study was approved by the Scientific Ethics Committee of The Capital Region of Denmark (protocol number H-4–2013-063) and complied with the Declaration of Helsinki.

Results
Two hundred patients were included at their first visit to the DOC, 3 patients withdrew consent and the final study population included 197 patients (Fig. 1). Of these, 39 patients (19.8%) were diagnosed with the following malignant diseases: 11 patients were diagnosed with lung cancer, 8 with colorectal cancer, 4 with prostate cancer, 2 with breast cancer, 2 with B-cell lymphoma and 12 with other malignant diagnoses.

During 12-month follow-up, none of the remaining 158 patients were subsequently diagnosed with cancer; 57 of these patients had no abnormalities detected, while 101 were diagnosed with other nonmalignant diseases, including infections ($n = 9$), endocrinologic- ($n = 8$), gastrointestinal- ($n = 28$), cardiovascular- ($n = 6$), hepatologic- ($n = 8$), pulmonary- ($n = 7$), inflammatory- ($n = 12$) and other disorders ($n = 23$).

Patient characteristics are presented in Table 1.

Patients in the group diagnosed with cancer were significantly older and had a higher burden of comorbidities and previous cancer diagnoses compared to the group with no cancer at follow-up (Table 1). A total of 135 patients reported a weight loss at their first consultation, and out of these, 25 (18.5%, $p = 0.53$) were diagnosed with cancer. Mean self-reported weight loss was not significantly different between the groups. Among standard biomarkers, albumin and hemoglobin were lower among the cancer patients, while CRP and ESR were elevated compared to patients without

Tumor Markers and Signatures

Table 1. Patient characteristics for the total patient population, patients without a final diagnosis of cancer and patients with a final diagnosis of cancer

	Total	No cancer			Cancer	p Values		
		All	No abnormality detected	Nonmalignant disease		vs. All	vs. NAD	vs. NMD
n (%)	197 (100)	158 (80.2)	57 (28.9)	101 (51.3)	39 (19.8)			
Sex, n (%)								
Female	101 (51.3)	85 (84.2)	34 (33.6)	51 (50.5)	16 (15.8)			
Male	96 (48.7)	73 (76.0)	23 (24.0)	50 (52.1)	23 (24.0)	0.21	0.10	0.35
Age, mean ± SD	62.7 ± 14.0	60.9 ± 14.4	57.0 ± 15.3	63.2 ± 13.4	69.7 ± 9.9	<0.0001	<0.0001	0.002
Weight loss (kg), mean ± SD	6.8 ± 6.0 (n = 177)	6.7 ± 6.0	6.7 ± 6.0 (n = 52)	6.7 ± 6.0 (n = 94)	7.4 ± 6.1 (n = 31)	0.58	0.63	0.60
Previous cancer, n (%)								
No	181 (91.9)	149 (82.3)	53 (29.3)	96 (53.0)	32 (17.7)			
Yes	16 (8.1)	9 (56.3)	4 (25.0)	5 (31.3)	7 (43.8)	0.02	0.11	0.04
Charlson score, n (%)								
Charlson score 0–1	157 (79.7)	131 (83.4)	50 (31.9)	81 (51.6)	26 (16.6)			
Charlson score >1	40 (20.3)	27 (67.5)	7 (17.5)	20 (50.0)	13 (32.5)	0.04	0.02	0.12
Biochemistry, median (IQR)								
Standard biomarkers								
Albumin (g/L)	38 (34–41) (n = 196)	38 (34–41)	40 (35–42) (n = 56)	38 (34–41)	35 (31-38) (n = 39)	0.003	0.0005	0.02
CRP (mg/L)	3 (1–11) (n = 179)	2 (1–7)	1 (1–4) (n = 47)	3 (1–9) (n = 95)	11 (6-39) (n = 37)	<0.0001	<0.0001	<0.0001
Hemoglobin (mmol/L)	8.3 (7.5–8.9)	8.4 (7.8–9.0)	8.5 (7.8–9.1)	8.4 (7.8–8.9)	7.5 (6.5-8.6)	0.001	0.002	0.005
LDH (IU/L)	164 (145–196) (n = 195)	162 (146–194)	157 (142–173) (n = 56)	167 (148–197) (n = 100)	173 (143-211)	0.25	0.08	0.53
WBC count (10^9/L)	7.7 (6.4–9.0)	7.6 (6.2–8.8)	7.5 (6.1–9.0)	7.6 (6.6–8.8)	8.3 (6.5-9.4)	0.05	0.05	0.11
ESR (mm)	12 (5–23) (n = 191)	9 (5–20)	7 (3–13) (n = 56)	12 (5–22) (n = 98)	23 (16-39) (n = 37)	<0.0001	<0.0001	0.001
Immunological biomarkers								
suPAR (ng/mL)	3.1 (2.3–4.6) (n = 190)	2.9 (2.2–4.2)	2.5 (2.0–3.1) (n = 55)	3.5 (2.5–4.6) (n = 97)	4.7 (3.1-6.8) (n = 38)	<0.0001	<0.0001	0.003
Ficolin-1 (ng/mL)	191.8 (80.4–295.9) (n = 185)	195.0 (81.3–287.6)	132.5 (60.0–270.9) (n = 53)	197.1 (87.3–287.6) (n = 93)	179.0 (75.4–411.0)	0.62	0.22	0.98
Ficolin-2 (μg/mL)	5.0 (3.1–7.4) (n = 184)	4.8 (2.9–7.0)	5.3 (3.5–7.3) (n = 53)	4.3 (2.6–6.9) (n = 92)	5.2 (3.8-8.2)	0.20	0.78	0.09
Ficolin-3 (μg/mL)	24.7 (10.8–40.0) (n = 185)	25.0 (11.7–40.2)	24.2 (11.5–34.8) (n = 53)	28.2 (12.6–44.0) (n = 93)	21.8 (7.9-34.5)	0.31	0.83	0.17
MBL (μg/mL)	1.99 (0.79–5.78) (n = 185)	2.08 (0.83–5.88)	2.08 (1.15–5.49) (n = 53)	2.07 (0.72–6.31) (n = 93)	1.89 (0.57-5.70)	0.59	0.60	0.65
Pentraxin-3 (ng/mL)	2.9 (1.5–5.2) (n = 185)	2.8 (1.5–5.1)	1.9 (1.5–4.2) (n = 53)	2.9 (1.5–5.2) (n = 93)	3.9 (2.7-6.1)	0.05	0.01	0.18

n is added in parentheses for variables with missing values.

Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IQR, interquartile range; LDH, lactate dehydrogenase; MBL, mannose-binding lectin; NAD, no abnormality detected; NMD, nonmalignant disease; SD, standard deviation; suPAR, soluble urokinase plasminogen activator receptor; WBC, white blood cell.

Table 2. Associations between potential risk factors and cancer

Variable	Univariate OR (95% CI)	p	Adjusted for age and sex OR (95% CI)	p	Adjusted for age, sex and CRP OR (95% CI)	p
Sex (male)	1.67 (0.82–3.41)	0.16	1.83 (0.87–3.82)	0.11	1.57 (0.70–3.53)	0.27
Age (per year)	1.05 (1.02–1.08)	0.0007	1.05 (1.02–1.09)	0.0006	1.03 (1.00–1.07)	0.06
Weight loss (per 5 kg)	0.92 (0.63–1.33)	0.65	0.90 (0.62–1.30)	0.57	0.92 (0.60–1.39)	0.69
Previous cancer	3.62 (1.26–10.44)	0.02	3.57 (1.14–11.23)	0.03	9.27 (2.20–39.01)	0.002
Charlson score	1.49 (1.08–2.05)	0.01	1.29 (0.93–1.81)	0.13	1.26 (0.88–1.78)	0.20
Albumin (log2)	0.92 (0.41–2.03)	0.83	1.46 (0.50–4.27)	0.49	2.60 (0.77–8.76)	0.12
LDH (log2)	2.04 (1.05–3.98)	0.04	1.71 (0.86–3.40)	0.13	1.46 (0.73–2.95)	0.29
Hemoglobin (log1.1)	0.64 (0.51–0.81)	0.0003	0.70 (0.54–0.90)	0.006	0.82 (0.62–1.08)	0.15
White blood cell count	1.18 (1.03–1.36)	0.02	1.18 (1.01–1.36)	0.03	1.11 (0.97–1.28)	0.14
CRP (log2)	1.50 (1.26–1.79)	<0.0001	1.41 (1.18–1.70)	0.0002	1.41 (1.18–1.70)	0.0002
ESR (log2)	1.62 (1.26–2.09)	0.0002	1.44 (1.10–1.89)	0.007	1.06 (0.76–1.46)	0.75
suPAR (log2)	3.36 (1.91–5.93)	<0.0001	2.58 (1.41–4.71)	0.002	2.33 (1.19–4.58)	0.01
Ficolin-1 (log2)	1.04 (0.82–1.32)	0.74	1.00 (0.77–1.28)	0.97	0.84 (0.64–1.11)	0.22
Ficolin-2 (log2)	1.34 (0.88–2.03)	0.17	1.40 (0.91–2.16)	0.13	1.25 (0.78–2.02)	0.36
Ficolin-3 (log2)	0.92 (0.71–1.17)	0.48	0.95 (0.73–1.23)	0.69	0.90 (0.67–1.19)	0.45
MBL (log2)	0.95 (0.77–1.16)	0.60	0.98 (0.79–1.21)	0.84	0.95 (0.75–1.19)	0.63
Pentraxin-3 (log2)	1.18 (0.89–1.55)	0.24	1.16 (0.85–1.58)	0.36	0.99 (0.68–1.43)	0.94

Abbreviations: CI, confidence interval; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase; MBL, mannose-binding lectin; suPAR, soluble urokinase plasminogen activator receptor.

cancer, patients with no abnormalities detected as well as patients with other nonmalignant diseases (Table 1). There was a borderline significant increase in white blood cell count among cancer patients (Table 1).

Patients with cancer had significantly higher suPAR and there was a borderline significant increase in pentraxin-3 compared to cancer-free patients, but none of the other PRRs were significantly different between the two groups (Table 1). The group of patients who had no abnormalities detected had markedly lower levels of CRP, ESR, suPAR and pentraxin-3, whereas albumin and hemoglobin was higher compared to patients diagnosed with cancer (Table 1). Patients diagnosed with other nonmalignant diseases had biomarker levels between that of cancer patients and patients with no abnormalities detected (Table 1).

Compared to the patients who had no abnormalities detected, the 12 patients with inflammatory disorders had significantly lower median (IQR) albumin [32 g/L (30–38), $p = 0.004$] and hemoglobin [7.8 mmol/L (7.0–8.4), $p = 0.03$] levels, and significantly higher median (IQR) CRP [11.5 mg/L (4.0–51.5), $p < 0.001$], ESR [21 mm (10–67), $p = 0.0008$] and suPAR [4.2 ng/mL (3.4–5.3), $p = 0.008$]. In addition, there was a trend toward increased ficolin-1 [244.7 ng/mL (146.9–454.4), $p = 0.06$] and pentraxin-3 [5.1 ng/mL (2.8–6.8), $p = 0.07$] levels in these patients.

In univariate logistic regression analyses, age, previous cancer, Charlson score, lactate dehydrogenase, hemoglobin, white blood cell count, CRP, ESR and suPAR were significantly associated with newly diagnosed cancer during follow-up (Table 2).

When adjusted for both age and sex, the following remained significantly associated with newly diagnosed cancer during follow-up: age, previous cancer, hemoglobin, white blood cell count, CRP, ESR and suPAR (Table 2). None of the soluble PRRs investigated were significantly associated with cancer diagnoses (Table 2).

When CRP was included in the adjusted analysis along with age and sex, only previous cancer, suPAR and CRP itself remained significantly associated with newly diagnosed cancer (Table 2).

To investigate the relationship between the three inflammatory biomarkers CRP, ESR and suPAR, we performed pairwise correlation analyses (Fig. 2). There was a strong positive correlation between CRP and ESR, and suPAR was also positively correlated with both CRP and ESR but to a lesser degree.

For the variables that remained significantly associated with incident cancer after adjustment for age and sex, we performed ROC curve analyses which resulted in the following AUCs (95% CI): age 0.675 (0.592–0.757), previous cancer 0.561 (0.498–0.625), hemoglobin 0.670 (0.565–0.775), white blood cell count 0.600 (0.496–0.704), CRP 0.761 (0.676–0.845), ESR 0.719 (0.627–0.810) and suPAR 0.721 (0.632–0.810).

Furthermore, to compare the predictive values of CRP and suPAR, we performed ROC curve and logistic regression

Tumor Markers and Signatures

Figure 2. Pairwise correlations between C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and soluble urokinase plasminogen activator receptor (suPAR) with Kendall's Tau-b correlation coefficient and linear regression line. Note the logarithmic axes.

analyses for a full model containing age, sex, previous cancer, CRP and suPAR and compared it with a model without CRP and a model without suPAR, respectively (Table 3). Combining both CRP and suPAR gave the highest AUC, sensitivity and an NPV of 93.4% (Table 3).

Discussion

In the present study, we evaluated known and novel biomarkers for their association with cancer. We found that hemoglobin, white blood cell count, CRP, ESR and the biomarker suPAR as well as previous cancer were associated with incident cancer after adjustment for both age and sex. When CRP was included in the adjusted analyses, only previous cancer, CRP and suPAR remained significantly associated with cancer; patients with previous cancer had the highest risk, and the AUC, sensitivity and NPV were improved when using CRP and suPAR together in the full model.

Fast diagnosis and subsequent initiation of correct treatment is vital for the overall prognosis in patients diagnosed with cancer.[35–37] Prolonging the diagnostic time interval increases the risk of a more advanced stage of the cancer at the time of diagnosis,[37] and survival is decreased with increasing stage of the disease at diagnosis.[36] Therefore, it is equally important to successfully and rapidly detect and diagnose cancers and not end the diagnostic process prematurely in patients who suffer from unrecognized serious diseases.

NSSC patients in fast-track DOCs pose a diagnostic challenge as they represent a heterogeneous group that suffer from a wide range of conditions, ranging from various cancers to infections, autoimmune diseases and healthy individuals.[2] Developing a diagnostic strategy that covers a broad variety of conditions is thus needed. A variety of biomarkers might help in screening and early detection of cancer[6] but many have not been evaluated in clinical use.

Although the biomarkers that were significantly associated with incident cancer trended toward abnormal values in patients with cancer, the median levels were virtually within the normal reference ranges, complicating clinical decision making. However, patients with no abnormalities detected had low CRP and suPAR levels—which were comparable to that of healthy people in the general population, including blood donors[38–40]—while patients receiving a diagnosis had increased CRP and suPAR levels, especially patients with incident cancer. Both CRP and suPAR contributed to an improved negative predictive value.

CRP, ESR and the novel inflammatory biomarker suPAR were all positively correlated with each other, with the strongest correlation found between CRP and ESR, consistent with previous research.[41] suPAR showed a weaker correlation with CRP and ESR, possibly because the biomarkers reflect different aspects of inflammation,[42] but, more likely, the difference between suPAR and the other inflammatory biomarkers could be due to the high expression of uPAR on cancer cells and surrounding stromal cells,[18–20] causing the increase in suPAR levels.

To our knowledge, this is the first study investigating the association between MBL, ficolin-1–3 and pentraxin-3 with incident cancer in a group of NSSC patients. Several studies have previously found an association between increased levels of these biomarkers and various organ-specific cancers.[7,8,10,12–15] For

Table 3. Logistic regression and ROC curve analysis

	AUC (95% CI)	p	Sensitivity (95% CI)	Specificity (95% CI)	NPV (95% CI)	PPV (95% CI)
Age, sex, previous cancer, CRP, suPAR	0.802 (0.723–0.881)	0.02[1]	0.806 (0.676–0.935)	0.728 (0.653–0.803)	0.934 (0.887–0.981)	0.439 (0.320–0.559)
Age, sex, previous cancer, CRP	0.759 (0.669–0.848)	0.07[2]	0.722 (0.576–0.869)	0.743 (0.669–0.816)	0.910 (0.857–0.963)	0.426 (0.302–0.550)
Age, sex, previous cancer, suPAR	0.776 (0.691–0.862)	0.13[2]	0.694 (0.544–0.845)	0.787 (0.718–0.856)	0.907 (0.854–0.959)	0.463 (0.330–0.596)

[1]Comparison of all three ROC curves, 2 degrees of freedom.
[2]Pairwise difference, compared to the full model, 1 degree of freedom.
Abbreviations: AUC, area under the curve; CI, confidence interval; CRP, C-reactive protein; NPV, negative predictive value; PPV, positive predictive value; suPAR, soluble urokinase plasminogen activator receptor.

example, pentraxin-3 levels have been found to be associated with lung cancer,[7] gliomas[8,9] and prostate cancer,[10] and high pentraxin-3 expression was found to be associated with poor survival in lung cancer.[7,43] Similarly, ficolin-1 (M-ficolin) has been associated with colorectal cancer,[12] and serum concentrations of ficolin-2 (L-ficolin) and ficolin-3 (H-ficolin) have been found to be increased in patients with malignant ovarian tumors compared to benign tumors or normal ovaries.[13,14] Also, MBL concentration has been found to be increased in patients with colorectal cancer,[15] advanced ovarian cancer,[16] glioblastoma multiforme[17] and thyroid cancer.[11]

On the contrary, serum and intrahepatic ficolin-2 levels have also been found to be decreased in patients with hepatocellular carcinoma compared to healthy persons,[44] and in children with cancer, serum ficolin-1 levels were not different from age-matched controls.[45] In our patient cohort, these PRRs did not add diagnostic information; pentraxin-3 was significantly higher in patients with cancer compared to patients with no abnormalities detected, but this association was not significant in the adjusted analyses. Even though these biomarkers are not relevant in cancer diagnostics for NSSC patients, they could still be useful in selected cancer cohorts. For the patients with inflammatory disorders, we observed a trend toward increased ficolin-1 and pentraxin-3 compared to patients with no abnormalities detected, suggesting that these PRRs are associated with inflammatory disease. This is supported by a systematic review and meta-analysis of 20 studies, where serum and plasma levels of pentraxin-3 were found to be elevated in autoimmune and inflammatory disorders compared to normal controls.[46] Similarly, plasma ficolin-1 has been found to be associated with rheumatoid arthritis,[47] but no significant difference was observed in ficolin-1 levels between systemic lupus erythematosus patients and healthy controls.[48]

Regarding the medical history factors examined, the Charlson comorbidity score showed a moderate association with cancer in NSSC patients, but this disappeared in the multivariate models.

Conflicting results exist concerning an association between involuntary weight loss and cancer for patients with nonspecific symptoms.[49,50] Interestingly, involuntary weight loss is often the major cause of concern of cancer and referral to the DOC, but it was not associated with incident cancer in our study. As weight loss in this study was self-reported it may be subject to recall bias. Similar to previous findings, cancer was only diagnosed in 18.5% of the patients who reported a weight loss.[1]

As a fast-track cancer pathway for NSSC patients, the purpose of the DOCs is to uncover hidden malignancy as well as exclude other present serious disease with a high degree of certainty. Discovery of a single or a collection of biomarkers that can rule out cancer with high specificity would be an invaluable addition to both cancer screening in the general population as well as in evaluation of patients with NSSC. The biomarker suPAR was shown to add significant and independent value to diagnosing cancer among patients with NSSC. Thus, combining suPAR with other independent factors may improve diagnostic efficacy. Interestingly, suPAR has previously been shown to carry prognostic value in cancer patients[27,51] and may as such add to both diagnosing and prognosticating cancer patients and accordingly uPAR is currently pursued as a promising imaging and radiotherapeutic target.[52–55] In any case, the positive and negative predictive values must be examined in a larger patient cohort to establish a clinical cutoff, and combining high sensitivity biomarkers with high specificity biomarkers to detect cancer[6] or constructing a predictive model consisting of biomarkers and clinical information would also require development and validation in cohorts larger than the present.

Strength and limitations

The examined cohort is small with few cases of cancers and therefore has character of a pilot study. As mentioned, weight loss was self-reported and may be subject to recall bias. Furthermore, the patients have a high degree of comorbidity and competing illnesses which makes the data more difficult to interpret, but this also strengthens the study as this patient sample is highly representative of the entire population of NSSC patients, making the results from this prospective study applicable in clinical practice. A larger patient cohort is also

Tumor Markers and Signatures

needed to establish how these biomarkers relate to other serious nonmalignant diagnoses.

Conclusion

In this study, previous cancer, CRP and suPAR were significantly associated with cancer diagnosis in patients with non-specific signs and symptoms. The PRRs ficolin-1–3, MBL and pentraxin-3 were not associated with cancer.

To examine the optimal screening strategy using biomarkers to identify cancer, more studies are required. The inflammatory biomarker suPAR is a promising new biomarker in the DOC setting, but the predictive values of suPAR in patients with NSSC should be examined in a larger patient material.

References

1. Ingeman ML, Christensen MB, Bro F, et al. The Danish cancer pathway for patients with serious non-specific symptoms and signs of cancer—a cross-sectional study of patient characteristics and cancer probability. *BMC Cancer* 2015;15:421.
2. Bislev LS, Bruun BJ, Gregersen S, et al. Prevalence of cancer in Danish patients referred to a fast-track diagnostic pathway is substantial. *Dan Med J* 2015;62:1–5.
3. Lebech A-M, Gaardsting A, Loft A, et al. Whole body 18F-FDG PET/CT is superior to CT as first line diagnostic imaging in patients referred with serious non-specific symptoms or signs of cancer: a randomized prospective study of 200 patients. *J Nucl Med* 2017; pii: jnumed.116.175380. doi: 10.2967/jnumed.116.175380.
4. Heikkilä K, Harris R, Lowe G, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. *Cancer Causes Control* 2009;20:15–26.
5. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. *J Clin Oncol* 2009;27:2217–24.
6. Uttley L, Whiteman BL, Woods HB, et al. Building the evidence base of blood-based biomarkers for early detection of cancer: a rapid systematic mapping review. *EBioMedicine* 2016;10:164–73.
7. Infante M, Allavena P, Garlanda C, et al. Prognostic and diagnostic potential of local and circulating levels of pentraxin 3 in lung cancer patients. *Int J Cancer* 2016;138:983–91.
8. Tung J-N, Ko C-P, Yang S-F, et al. Inhibition of pentraxin 3 in glioma cells impairs proliferation and invasion in vitro and in vivo. *J Neurooncol* 2016;129:201–9.
9. Locatelli M, Ferrero S, Martinelli Boneschi F, et al. The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomas. *J Neuroimmunol* 2013; 260:99–106.
10. Stallone G, Cormio L, Netti GS, et al. Pentraxin 3: a novel biomarker for predicting progression from prostatic inflammation to prostate cancer. *Cancer Res* 2014;74:4230–8.
11. Lu Y, Sun G, Liu G, et al. Clinical significance of mannose-binding lectin expression in thyroid carcinoma tissues. *Pathol Oncol Res* 2013;19:259–66.
12. Storm L, Christensen IJ, Jensenius JC, et al. Evaluation of complement proteins as screening markers for colorectal cancer. *Cancer Immunol Immunother* 2015;64:41–50.
13. Szala A, Sawicki S, Swierzko AS, et al. Ficolin-2 and ficolin-3 in women with malignant and benign ovarian tumours. *Cancer Immunol Immunother* 2013;62:1411–9.
14. Andersen JD, Boylan KLM, Xue FS, et al. Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis. *Electrophoresis* 2010;31:599–610.
15. Ytting H, Jensenius JC, Christensen IJ, et al. Increased activity of the mannan-binding lectin complement activation pathway in patients with colorectal cancer. *Scand J Gastroenterol* 2004;39:674–9.
16. Swierzko AS, Szala A, Sawicki S, et al. Mannose-binding lectin (MBL) and MBL-associated serine protease-2 (MASP-2) in women with malignant and benign ovarian tumours. *Cancer Immunol Immunother* 2014;63:1129–40.
17. Bouwens TAM, Trouw LA, Veerhuis R, et al. Complement activation in glioblastoma multiforme pathophysiology: evidence from serum levels and presence of complement activation products in tumor tissue. *J Neuroimmunol* 2015; 278:271–6.
18. Dohn LH, Pappot H, Iversen BR, et al. uPAR expression pattern in patients with urothelial carcinoma of the bladder—possible clinical implications. *PLoS One* 2015;10:e0135824.
19. Lærum OD, Ovrebo K, Skarstein A, et al. Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry. *Int J Cancer* 2012;131:558–69.
20. Illemann M, Laerum OD, Hasselby JP, et al. Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer. *Cancer Med* 2014;3:855–64.
21. Chounta A, Ellinas C, Tzanetakou V, et al. Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma. *Liver Int* 2015;35:601–7.
22. Cobos E, Jumper C, Lox C. Pretreatment determination of the serum urokinase plasminogen activator and its soluble receptor in advanced small-cell lung cancer or non-small-cell lung cancer. *Clin Appl Thromb* 2003;9:241–6.
23. Sorio C, Mafficini A, Furlan F, et al. Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. *BMC Cancer* 2011;11:448.
24. Lomholt AF, Christensen IJ, Høyer-Hansen G, et al. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients. *Acta Oncol* 2010;49:805–11.
25. Miyake H, Hara I, Yamanaka K, et al. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. *Prostate* 1999;39:123–9.
26. Usnarska-Zubkiewicz L, Strutyńska-Karpińska M, Zubkiewicz-Kucharska A, et al. Soluble urokinase-type plasminogen activator receptor and ferritin concentration in patients with advanced alimentary tract carcinoma. relationship to localization, surgical treatment and the stage of the disease—preliminary report. *Adv Clin Exp Med* 2014;23:959–67.
27. Tarpgaard LS, Christensen IJ, Høyer-Hansen G, et al. Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. *Int J Cancer* 2015;137:2470–7.
28. Langkilde A, Hansen TW, Ladelund S, et al. Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals. *Cancer. Epidemiol Biomarkers Prev* 2011;20:609–18.
29. Garred P, Madsen HO, Kurtzhals JA, et al. Diallelic polymorphism may explain variations of the blood concentration of mannan-binding protein in Eskimos, but not in black Africans. *Eur J Immunogenet* 1992;19:403–12.
30. Bastrup-Birk S, Skjoedt M-O, Munthe-Fog L, et al. Pentraxin-3 serum levels are associated with disease severity and mortality in patients with systemic inflammatory response syndrome. *PLoS One* 2013;8:e73119.
31. Munthe-Fog L, Hummelshøj T, Hansen BE, et al. The impact of FCN2 polymorphisms and haplotypes on the Ficolin-2 serum levels. *Scand J Immunol* 2007;65:383–92.
32. Munthe-Fog L, Hummelshøj T, Ma YJ, et al. Characterization of a polymorphism in the coding sequence of FCN3 resulting in a Ficolin-3 (Hakata antigen) deficiency state. *Mol Immunol* 2008;45:2660–6.
33. Munthe-Fog L, Hummelshoj T, Honoré C, et al. Variation in FCN1 affects biosynthesis of ficolin-1 and is associated with outcome of systemic inflammation. *Genes Immun* 2012;13:515–22.
34. Youden WJ. Index for rating diagnostic tests. *Cancer* 1950;3:32–5.
35. Jensen H, Torring ML, Olesen F, et al. Diagnostic intervals before and after implementation of cancer patient pathways—a GP survey and registry based comparison of three cohorts of cancer patients. *BMC Cancer* 2015;15:308.
36. McPhail S, Johnson S, Greenberg D, et al. Stage at diagnosis and early mortality from cancer in England. *Br J Cancer* 2015;112 Suppl:S108–15.

37. Tørring ML, Frydenberg M, Hansen RP, et al. Evidence of increasing mortality with longer diagnostic intervals for five common cancers: a cohort study in primary care. *Eur J Cancer* 2013;49:2187–98.

38. Haastrup E, Grau K, Eugen-olsen J, et al.. Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants. 2014;9:1–7.

39. Persson M, Ostling G, Smith G, et al. Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease. *Stroke* 2014;45:18–23.

40. Sørensen MH, Gerke O, Eugen-Olsen J, et al. Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects. *Atherosclerosis* 2014;237:60–6.

41. Enocsson H, Wetterö J, Skogh T, et al. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus. *Transl Res* 2013;162:287–96.

42. Lyngbæk S, Sehestedt T, Marott JL, et al. CRP and suPAR are differently related to anthropometry and subclinical organ damage. *Int J Cardiol* 2013;167:781–5.

43. Liu C, Yao Y, Wang W. Pentraxin-3 as a prognostic marker in patients with small-cell lung cancer. *Med Oncol* 2014;31:207.

44. Chen T, Hu Y, Ding Q, et al. Serum ficolin-2 concentrations are significantly changed in patients with hepatitis B virus infection and liver diseases. *Virol Sin* 2015;30:249–60.

45. Schlapbach LJ, Thiel S, Aebi C, et al. M-ficolin in children with cancer. *Immunobiology* 2011;216:633–8.

46. Huang X, Zhang L, Duan Y, et al. Association of pentraxin 3 with autoimmune diseases: a systematic review and meta-analysis. *Arch Med Res* 2016;47:223–31.

47. Ammitzbøll CG, Thiel S, Jensenius JC, et al. Brief report: M-ficolin levels reflect disease activity and predict remission in early rheumatoid arthritis. *Arthritis Rheum* 2013;65:3045–50.

48. Hein E, Nielsen LA, Nielsen CT, et al. Ficolins and the lectin pathway of complement in patients with systemic lupus erythematosus. *Mol Immunol* 2014;63:209–14.

49. Baicus C, Rimbas M, Baicus A, et al. Cancer and involuntary weight loss: failure to validate a prediction score. *PLoS One* 2014;9:1–7.

50. Hernández JL, Matorras P, Riancho JA, et al. Involuntary weight loss without specific symptoms: a clinical prediction score for malignant neoplasm. *QJM - Mon J Assoc Physicians* 2003;96:649–55.

51. Fidan E, Mentese A, Ozdemir F, et al. Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer. *Med Oncol* 2013;30:540.

52. Persson M, Rasmussen P, Madsen J, et al. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts. *Nucl Med Biol* 2012;39:962–9.

53. Persson M, Juhl K, Rasmussen P, et al. UPAR targeted radionuclide therapy with 177Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer. *Mol Pharm* 2014;11:2796–806.

54. Persson M, Skovgaard D, Brandt-Larsen M, et al. First-in-human uPAR PET: imaging of cancer aggressiveness. *Theranostics* 2015;5:1303–16.

55. Skovgaard D, Persson M, Brandt-larsen M, et al. Safety, dosimetry and tumor detection ability of 68 Ga-NOTA-AE105—a novel radioligand for uPAR PET imaging: first-in-humans study. *J Nucl Med* 2017;58:379–386.

Tumor Markers and Signatures